ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D.,
Chairman and Chief Executive Officer, will present at the LEERINK Partners Rare Disease Roundtable Series in New York City on
Wednesday, September 27, 2017, at 9:30 a.m. Eastern Time. A live webcast of the event will be available through the Events and
Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com, and a replay of the presentation will be available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important
unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing
loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with
biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for Meniere's disease and other
vestibular disorders (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is
headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol
"EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com
Media contact: David Schull, Russo Partners, 1-858-717-2310,
david.schull@russopartnersllc.com
